At least three pharmaceutical companies agreed to reference pricing language in US contracts for COVID-19 vaccines, with one company even accepting language that could give the government unilateral discretion to “determine a fair and reasonable price.”
Such contract clauses weaken some of the drug industry’s core arguments against the use of reference pricing and price controls,...







